Costs of HIV prevention among out-of-treatment drug-using women: results of a randomized controlled trial.
OBJECTIVE
We developed a micro-costing methodology to estimate the real resource costs consumed by delivery of the National Institute on Drug Abuse (NIDA) Cooperative Agreement Standard Intervention (SI) for human immunodeficiency virus (HIV) prevention, plus two enhanced modules, in a three-arm randomized controlled trial (RCT) among drug-using women. To our knowledge, this is the first micro-costing study of the SI and enhanced modules and the first of its kind targeting drug-using women.


METHODS
We conducted a micro-costing study alongside a three-arm RCT to estimate costs of (1) the modified NIDA SI; (2) the SI and a well woman exam (SI+WWE); and (3) the SI, WWE, and four educational sessions (SI+WWE+4ES) to prevent HIV and sexually transmitted diseases in at-risk, drug-using women in St. Louis, Missouri.


RESULTS
The cost of the SI that all 501 participants received was approximately $227 per person. The additional costs for the WWE and 4ES were approximately $145 and $942 per person, respectively. Total program costs for the SI (n = 501) were $113,869; additional costs for the SI+WWE (n = 342) were $49,403 and for the SI+WWE+4ES (n = 170) were $160,189. The main cost component for the SI (64% of total costs) was testing costs, whereas building and facilities costs were the main cost component for the SI+WWE+4ES (75% of total costs).


CONCLUSIONS
This study provides accurate estimates of the real costs for standard and enhanced HIV interventions for policy makers seeking to implement targeted HIV-prevention programs with scarce resources.
Ruger
Jennifer Prah
JP
Department of Epidemiology and Public Health, Yale School of Medicine, 60 College St., PO Box 208034, New Haven, CT 06520-8034, USA. jennifer.ruger@yale.edu
Ben Abdallah
Arbi
A
Cottler
Linda
L
D017280:Condoms / Q000191:economics; D019111:Single-Use Internal Condom / Q000191:economics; D003365:Costs and Cost Analysis; D005260:Female; D015658:HIV Infections / Q000175:diagnosis / Q000191:economics* / Q000517:prevention & control*; D006801:Humans; D010353:Patient Education as Topic / Q000191:economics*; D012749:Sexually Transmitted Diseases / Q000175:diagnosis / Q000517:prevention & control; D019966:Substance-Related Disorders; D014626:Vaginal Smears / Q000191:economics*
Med Care. 2006 Nov;44(11):990-7
17063130
J Health Econ. 1997 Feb;16(1):1-31
10167341
BMJ. 2004 Jul 17;329(7458):121-2
15258043
Annu Rev Public Health. 2006;27:261-75
16533117
AIDS. 2005 Nov 18;19(17):2025-9
16260910
J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Sep 1;16(1):54-62
9377126
J Clin Psychiatry. 1999;60 Suppl 3:54-6; discussion 57-8
10073379
Am J Prev Med. 2003 Aug;25(2):112-21
12880878
Health Serv Res. 2001 Jun;36(2):335-55
11409816
Int J Technol Assess Health Care. 1990;6(1):57-75
2113891
Am J Public Health. 1998 Aug;88(8):1239-42
9702159
Public Health Rep. 1996;111 Suppl 1:115-22
8862166
AIDS. 2001 May 4;15(7):917-28
11399964
J Acquir Immune Defic Syndr. 2000 Oct 1;25(2):164-72
11103047
Am J Prev Med. 2002 Jul;23(1):7-12
12093417
Public Health Rep. 1998 Jun;113 Suppl 1:31-41
9722808
J Public Health Manag Pract. 2004 Mar-Apr;10(2):130-9
14967980
AIDS Care. 2000 Jun;12(3):321-32
10928210